(openPR) - Another of the laboratories within the M-Scan group, M-Scan Ltd (Wokingham, UK), has successfully completed regulatory inspections conducted by both the United States FDA and the UK MHRA. M-Scan Ltd, which has been fully compliant with GLP since 1992, now joins the other M-Scan labs in offering analytical services throughout the clinical development phases of drug discovery. In a new initiative, the MHRA has introduced a “certificate of GMP inspection” and M-Scan Ltd will be amongst the first laboratories to receive this. Please contact M-Scan Ltd for a copy.
Dr Fiona Greer
Director, Biochemical Services
M-Scan Ltd
3, Millars Business Centre, Fishponds Close
Wokingham, Berkshire, RG41 2TZ, UK
Tel: 0118 989 6940
Fax: 0118 989 6941 services.ltd@m-scan.com www.m-scan.com
M-Scan provides specialised mass spectrometry and related services for the characterisation of pharmaceuticals and biotech products. Studies involve recombinant and native molecules at all stages of the product development pipeline, including research (Proteomics), process QC, bioanalysis and regulatory approval. Structural analysis services are tailored to the requirements of the FDA “well-characterized” or “specified” molecule definition and a full analysis package is provided for characterisation under the ICH Q6B guidelines.
The four laboratories in the M-Scan Group (UK, Switzerland, Germany, and the States) are equipped with over 25 mass spectrometers, providing a range of ionisation and detection techniques for optimum sensitivity and versatility. The labs are supported by offices in UK, Germany, S. Korea, Singapore and India.
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
Newsfeed
